Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Freedom of Information Litigation Puts the Spotlight on Valuation Practices

This article was originally published in Start Up

Executive Summary

VC concern over efforts to compel public pension funds to disclose information regarding their private equity partners has largely focused on the release of internal rate of return statistics. A recent court ruling, however, suggests that the legal grounds for protecting the confidentiality of such data are tenuous at best. The more significant question is whether public pension funds can be forced to disclose their venture fund investees' valuations of individual portfolio companies. Public dissemination of that information would reveal the inconsistent (and possibly arbitrary) methods use to value companies.

You may also be interested in...

The Value of Me-Too's in the Context of OTC Switches

At Windhover's annual Marketing Pharmaceutical Innovation (MPI) conference in November, industry executives wrestled with an emerging dilemma -- how to win managed care's support for drugs that exhibit only minor improvements to existing products, while new over-the-counter (OTC) options surface.

Private Equity Fund IRRs Disclosed But Questions Linger

Kicking and screaming, venture capital is being dragged into maturity. Demands are growing for greater disclosure in this secretive world. And with venture funds seeming to require more and more money, the VCs may not be able to resist the trend.

Why Clinical Trials Fail Unexpectedly

Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts